Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
International Urology and Nephrology
Published in: International Urology and Nephrology 2/2015

01-02-2015 | Urology - Original Paper

Histopathological classification criteria of rat model of chronic prostatitis/chronic pelvic pain syndrome

Authors: Xianjin Wang, Shan Zhong, Tianyuan Xu, Leilei Xia, Xiaohua Zhang, Zhaowei Zhu, Minguang Zhang, Zhoujun Shen

Published in: International Urology and Nephrology | Issue 2/2015

Login to get access

Abstract

Objective

A variety of murine models of experimental prostatitis that mimic the phenotype of human chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) have been developed. However, there is still a lack of explicit diagnosis criteria about those animal model. Our study is to establish histopathological classification criteria, which will be conducive to evaluate the animal models.

Methods

We firstly established a rat model of experimental autoimmune prostatitis that is considered a valid model for CP/CPPS. For modelling, male Sprague–Dawley rats were immunized with autologous prostate tissue homogenate supernatant emulsified with complete Freund’s adjuvant by subcutaneous injection into abdominal flank and simultaneously immunized with pertussis–diphtheria–tetanus vaccine by intraperitoneal injection. Three immunizations were administered semimonthly. At the 45th day, animals were killed, and prostate tissues were examined for morphology.

Results

Histologically, the prostate tissues were characterized by lymphoproliferation, atrophy of acini, and chronic inflammatory cells infiltration in the stromal connective tissue around the acini or ducts. Finally, we built histopathological classification criteria incorporating inflammation locations (mesenchyme, glands, periglandular tissues), ranges (focal, multifocal, diffuse), and grades (grade I–IV). To verify the effectiveness and practicability of the histopathological classification criteria, we conducted the treatment study with one of the alpha blockers, tamsulosin.

Conclusion

The histopathological classification criteria of rat model of CP/CPPS will serve for further research of the pathogenesis and treatment strategies of the disease.
Literature
1.
Schaeffer AJ (2006) Clinical practice. Chronic prostatitis and the chronic pelvic pain syndrome. N Engl J Med 355:1690–1698PubMedCrossRef
2.
Collins MM, Stafford RS, O’Leary MP, Barry MJ (1998) How common is prostatitis? A national survey of physician visits. J Urol 159:1224–1228PubMedCrossRef
3.
4.
Krieger JN, Nyberg L Jr, Nickel JC (1999) NIH consensus definition and classification of prostatitis. JAMA 282:236–237PubMedCrossRef
5.
Nickel JC, Nyberg LM, Hennenfent M (1999) Research guidelines for chronic prostatitis: consensus report from the first national institutes of health international prostatitis collaborative network. Urology 54:229–233PubMedCrossRef
6.
Marszalek M, Wehrberger C, Temml C, Ponholzer A, Berger I, Madersbacher S (2009) Chronic pelvic pain and lower urinary tract symptoms in both sexes: analysis of 2749 participants of an urban health screening project. Eur Urol 55:499–507PubMedCrossRef
7.
Habermacher GM, Chason JT, Schaeffer AJ (2006) Prostatitis/chronic pelvic pain syndrome. Annu Rev Med 57:195–206PubMedCrossRef
8.
Nickel JC, Downey J, Hunter D, Clark J (2001) Prevalence of prostatitis-like symptoms in a population based study using the national institutes of health chronic prostatitis symptom index. J Urol 165:842–845PubMedCrossRef
9.
Wagenlehner FM, van Till JW, Magri V, Perletti G, Houbiers JG, Weidner W et al (2013) National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI) symptom evaluation in multinational cohorts of patients with chronic prostatitis/chronic pelvic pain syndrome. Eur Urol 63:953–959PubMedCrossRef
10.
Walz J, Perrotte P, Hutterer G, Suardi N, Jeldres C, Benard F et al (2007) Impact of chronic prostatitis-like symptoms on the quality of life in a large group of men. BJU Int 100:1307–1311PubMedCrossRef
11.
12.
13.
Tripp DA, Nickel JC, Ross S, Mullins C, Stechyson N (2009) Prevalence, symptom impact and predictors of chronic prostatitis-like symptoms in Canadian males aged 16–19 years. BJU Int 103:1080–1084PubMedCrossRef
14.
Shoskes DA, Nickel JC, Rackley RR, Pontari MA (2009) Clinical phenotyping in chronic prostatitis/chronic pelvic pain syndrome and interstitial cystitis: a management strategy for urologic chronic pelvic pain syndromes. Prostate Cancer Prostatic Dis 12:177–183PubMedCrossRef
15.
Sonmez NC, Kiremit MC, Guney S, Arisan S, Akca O, Dalkilic A (2011) Sexual dysfunction in type III chronic prostatitis (CP) and chronic pelvic pain syndrome (CPPS) observed in Turkish patients. Int Urol Nephrol 43:309–314PubMedCrossRef
16.
Ismail M, Mackenzie K, Hashim H (2013) Contemporary treatment options for chronic prostatitis/chronic pelvic pain syndrome. Drugs Today (Barc) 49:457–462CrossRef
17.
Anothaisintawee T, Attia J, Nickel JC, Thammakraisorn S, Numthavaj P, McEvoy M et al (2011) Management of chronic prostatitis/chronic pelvic pain syndrome: a systematic review and network meta-analysis. JAMA 305:78–86PubMedCrossRef
18.
Tang P, Xie KJ, Wang B, Deng XR, Ou RB (2010) Antibacterial therapy improves the effectiveness of prostate cancer detection using prostate-specific antigen in patients with asymptomatic prostatitis. Int Urol Nephrol 42:13–18PubMedCrossRef
19.
Tomaskovic I, Ruzic B, Trnski D, Kraus O (2009) Chronic prostatitis/chronic pelvic pain syndrome in males may be an autoimmune disease, potentially responsive to corticosteroid therapy. Med Hypotheses 72:261–262PubMedCrossRef
20.
Ku JH, Kim SW, Paick JS (2005) Epidemiologic risk factors for chronic prostatitis. Int J Androl 28:317–327PubMedCrossRef
21.
Pontari MA, McNaughton-Collins M, O’Leary MP, Calhoun EA, Jang T, Kusek JW et al (2005) A case–control study of risk factors in men with chronic pelvic pain syndrome. BJU Int 96:559–565PubMedCrossRef
22.
Krieger JN, Ross SO, Riley DE (2002) Chronic prostatitis: epidemiology and role of infection. Urology 60:8–13PubMedCrossRef
23.
Vykhovanets EV, Resnick MI, MacLennan GT, Gupta S (2007) Experimental rodent models of prostatitis: limitations and potential. Prostate Cancer Prostatic Dis 10:15–29PubMedCrossRef
24.
Rivero VE, Motrich RD, Maccioni M, Riera CM (2007) Autoimmune etiology in chronic prostatitis syndrome: an advance in the understanding of this pathology. Crit Rev Immunol 27:33–46PubMedCrossRef
25.
Altuntas CZ, Daneshgari F, Veizi E, Izgi K, Bicer F, Ozer A et al (2013) A novel murine model of chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) induced by immunization with a spermine binding protein (p25) peptide. Am J Physiol Regul Integr Comp Physiol 304:R415–R422PubMedCentralPubMedCrossRef
26.
Galmarini M, Riera CM, Pesoa S, Vullo C, Vottero-Cima E (1981) Induction of humoral autoimmune response to rat male accessory glands. Medicina (B Aires) 41:349–353
27.
Maccioni M, Rivero V, Riera CM (1996) Autoantibodies against rat prostate antigens. Association of specific IGG2b and IGG2c with the DTH response. J Autoimmun 9:485–491PubMedCrossRef
28.
Keetch DW, Humphrey P, Ratliff TL (1994) Development of a mouse model for nonbacterial prostatitis. J Urol 152:247–250PubMed
29.
Rivero V, Carnaud C, Riera CM (2002) Prostatein or steroid binding protein (PSBP) induces experimental autoimmune prostatitis (EAP) in NOD mice. Clin Immunol 105:176–184PubMedCrossRef
30.
Penna G, Amuchastegui S, Cossetti C, Aquilano F, Mariani R, Giarratana N et al (2007) Spontaneous and prostatic steroid binding protein peptide-induced autoimmune prostatitis in the nonobese diabetic mouse. J Immunol 179:1559–1567PubMedCrossRef
31.
Maccioni M, Rivero VE, Riera CM (1998) Prostatein (or rat prostatic steroid binding protein) is a major autoantigen in experimental autoimmune prostatitis. Clin Exp Immunol 112:159–165PubMedCentralPubMedCrossRef
32.
Liu KJ, Chatta GS, Twardzik DR, Vedvick TS, True LD, Spies AG et al (1997) Identification of rat prostatic steroid-binding protein as a target antigen of experimental autoimmune prostatitis: implications for prostate cancer therapy. J Immunol 159:472–480PubMed
33.
Pontari MA (2013) Etiology of chronic prostatitis/chronic pelvic pain syndrome: psychoimmunoneurendocrine dysfunction (PINE syndrome) or just a really bad infection? World J Urol 31:725–732PubMedCrossRef
34.
Nickel JC, Alexander RB, Schaeffer AJ, Landis JR, Knauss JS, Propert KJ et al (2003) Leukocytes and bacteria in men with chronic prostatitis/chronic pelvic pain syndrome compared to asymptomatic controls. J Urol 170:818–822PubMedCrossRef
35.
Keith IM, Jin J, Neal D Jr, Teunissen BD, Moon TD (2001) Cell relationship in a Wistar rat model of spontaneous prostatitis. J Urol 166:323–328PubMedCrossRef
36.
Naslund MJ, Strandberg JD, Coffey DS (1988) The role of androgens and estrogens in the pathogenesis of experimental nonbacterial prostatitis. J Urol 140:1049–1053PubMed
37.
Seo SI, Lee SJ, Kim JC, Choi YJ, Sw SW, Hwang TK et al (2003) Effects of androgen deprivation on chronic bacterial prostatitis in a rat model. Int J Urol 10:485–491PubMedCrossRef
38.
Robinette CL (1988) Sex-hormone-induced inflammation and fibromuscular proliferation in the rat lateral prostate. Prostate 12:271–286PubMedCrossRef
39.
Yatkin E, Bernoulli J, Talvitie EM, Santti R (2009) Inflammation and epithelial alterations in rat prostate: impact of the androgen to oestrogen ratio. Int J Androl 32:399–410PubMedCrossRef
40.
Bernoulli J, Yatkin E, Konkol Y, Talvitie EM, Santti R, Streng T (2008) Prostatic inflammation and obstructive voiding in the adult Noble rat: impact of the testosterone to estradiol ratio in serum. Prostate 68:1296–1306PubMedCrossRef
41.
Matsumoto S, Kawai Y, Oka M, Oyama T, Hashizume K, Wada N et al (2013) Bladder function in 17β-estradiol-induced nonbacterial prostatitis model in Wistar rat. Int Urol Nephrol 45:749–754PubMedCrossRef
42.
Qi X, Han L, Liu X, Zhi J, Zhao B, Chen D et al (2012) Prostate extract with aluminum hydroxide injection as a novel animal model for chronic prostatitis/chronic pelvic pain syndrome. Urology 80(1389):e1389–e1389
43.
Chung SD, Lin HC (2013) Association between chronic prostatitis/chronic pelvic pain syndrome and anxiety disorder: a population-based study. PLoS ONE 8:e64630PubMedCentralPubMedCrossRef
44.
Anderson RU, Orenberg EK, Morey A, Chavez N, Chan CA (2009) Stress induced hypothalamus-pituitary-adrenal axis responses and disturbances in psychological profiles in men with chronic prostatitis/chronic pelvic pain syndrome. J Urol 182:2319–2324PubMedCrossRef
45.
Gatenbeck L, Aronsson A, Dahlgren S, Johansson B, Stromberg L (1987) Stress stimuli-induced histopathological changes in the prostate: an experimental study in the rat. Prostate 11:69–76PubMedCrossRef
46.
Takechi S, Yokoyama M, Tanji N, Nishio S, Araki N (1999) Nonbacterial prostatitis caused by partial urethral obstruction in the rat. Urol Res 27:346–350PubMedCrossRef
47.
Sharma OP, Adlercreutz H, Strandberg JD, Zirkin BR, Coffey DS, Ewing LL (1992) Soy of dietary source plays a preventive role against the pathogenesis of prostatitis in rats. J Steroid Biochem Mol Biol 43:557–564PubMedCrossRef
48.
Kwon SM, Kim SI, Chun DC, Cho NH, Chung BC, Park BW et al (2001) Development of rat prostatitis model by oral administration of isoflavone and its characteristics. Yonsei Med J 42:395–404PubMedCrossRef
49.
Motrich RD, Maccioni M, Riera CM, Rivero VE (2007) Autoimmune prostatitis: state of the art. Scand J Immunol 66:217–227PubMedCrossRef
50.
Zhang ZY, Schluesener HJ (2012) HDAC inhibitor MS-275 attenuates the inflammatory reaction in rat experimental autoimmune prostatitis. Prostate 72:90–99PubMedCrossRef
51.
Penna G, Fibbi B, Maggi M, Adorini L (2009) Prostate autoimmunity: from experimental models to clinical counterparts. Expert Rev Clin Immunol 5:577–586PubMedCrossRef
52.
Motrich RD, Maccioni M, Ponce AA, Gatti GA, Oberti JP, Rivero VE (2006) Pathogenic consequences in semen quality of an autoimmune response against the prostate gland: from animal models to human disease. J Immunol 177:957–967PubMedCrossRef
53.
Ludwig M, Steltz C, Huwe P, Schaffer R, Altmannsberger M, Weidner W (2001) Immunocytological analysis of leukocyte subpopulations in urine specimens before and after prostatic massage. Eur Urol 39:277–282PubMedCrossRef
54.
Kouiavskaia DV, Southwood S, Berard CA, Klyushnenkova EN, Alexander RB (2009) T-cell recognition of prostatic peptides in men with chronic prostatitis/chronic pelvic pain syndrome. J Urol 182:2483–2489PubMedCentralPubMedCrossRef
55.
Dunphy EJ, Eickhoff JC, Muller CH, Berger RE, McNeel DG (2004) Identification of antigen-specific IgG in sera from patients with chronic prostatitis. J Clin Immunol 24:492–502PubMedCrossRef
56.
Hou Y, DeVoss J, Dao V, Kwek S, Simko JP, McNeel DG et al (2009) An aberrant prostate antigen-specific immune response causes prostatitis in mice and is associated with chronic prostatitis in humans. J Clin Invest 119:2031–2041PubMedCentralPubMed
57.
Ponniah S, Arah I, Alexander RB (2000) PSA is a candidate self-antigen in autoimmune chronic prostatitis/chronic pelvic pain syndrome. Prostate 44:49–54PubMedCrossRef
58.
Rivero VE, Iribarren P, Riera CM (1995) Mast cells in accessory glands of experimentally induced prostatitis in male Wistar rats. Clin Immunol Immunopathol 74:236–242PubMedCrossRef
59.
Depiante-Depaoli M, Pacheco-Rupil B, Britos S, Casas A (1984) Experimental autoimmune damage to rat male accessory glands. I. Transfer of autoimmune response by spleen cells. Am J Reprod Immunol 5:9–14PubMedCrossRef
60.
Depiante-Depaoli M, Pacheco-Rupil B (1985) Experimental autoimmunity to rat male accessory glands (MAG): circulating antibodies, immunoglobulins bound to target glands, and immunoglobulins-secreting cells. Am J Reprod Immunol Microbiol 7:32–38PubMed
61.
Casas-Ingaramo A, Depiante-Depaoli M, Pacheco-Rupil B (1991) Activation of cytotoxic cells by syngeneic prostate antigens in experimental autoimmune vesiculo-prostatitis. Autoimmunity 9:151–157PubMedCrossRef
62.
Penna G, Amuchastegui S, Cossetti C, Aquilano F, Mariani R, Sanvito F et al (2006) Treatment of experimental autoimmune prostatitis in nonobese diabetic mice by the vitamin D receptor agonist elocalcitol. J Immunol 177:8504–8511PubMedCrossRef
63.
Jackson CM, Flies DB, Mosse CA, Parwani A, Hipkiss EL, Drake CG (2013) Strain-specific induction of experimental autoimmune prostatitis (EAP) in mice. Prostate 73:651–656PubMedCentralPubMedCrossRef
64.
Breser ML, Motrich RD, Sanchez LR, Mackern-Oberti JP, Rivero VE (2013) Expression of CXCR3 on specific T cells is essential for homing to the prostate gland in an experimental model of chronic prostatitis/chronic pelvic pain syndrome. J Immunol 190:3121–3133PubMedCrossRef
65.
Klyushnenkova EN, Kouiavskaia DV, Kodak JA, Vandenbark AA, Alexander RB (2007) Identification of HLA-DRB1*1501-restricted T-cell epitopes from human prostatic acid phosphatase. Prostate 67:1019–1028PubMedCrossRef
66.
Fong L, Ruegg CL, Brockstedt D, Engleman EG, Laus R (1997) Induction of tissue-specific autoimmune prostatitis with prostatic acid phosphatase immunization: implications for immunotherapy of prostate cancer. J Immunol 159:3113–3117PubMed
67.
Motrich RD, van Etten E, Baeke F, Riera CM, Mathieu C, Rivero VE (2010) Crucial role of interferon-gamma in experimental autoimmune prostatitis. J Urol 183:1213–1220PubMedCrossRef
68.
Zhang ZY, Zug C, Schluesener HJ (2011) Sphingosine 1-phosphate receptor modulator FTY720 suppresses rat experimental autoimmune prostatitis. Scand J Immunol 73:546–553PubMedCrossRef
69.
Cunha GR, Donjacour AA, Cooke PS, Mee S, Bigsby RM, Higgins SJ et al (1987) The endocrinology and developmental biology of the prostate. Endocr Rev 8:338–362PubMedCrossRef
70.
Pontari MA, Ruggieri MR (2008) Mechanisms in prostatitis/chronic pelvic pain syndrome. J Urol 179:S61–S67PubMedCrossRef
71.
Byun JS, Yoon TK, Rhee HW, Kim JH, Shin JS, Kim HS et al (2012) Chronic pelvic pain syndrome and semen quality of Korean men in their fourth decade. J Androl 33:876–885PubMedCrossRef
72.
Meng J, Mostaghel EA, Vakar-Lopez F, Montgomery B, True L, Nelson PS (2011) Testosterone regulates tight junction proteins and influences prostatic autoimmune responses. Horm Cancer 2:145–156PubMedCrossRef
73.
Sugimoto M, Oka M, Tsunemori H, Yamashita M, Kakehi Y (2011) Effect of a phytotherapeutic agent, Eviprostat®, on prostatic and urinary cytokines/chemokines in a rat model of nonbacterial prostatitis. Prostate 71:438–444PubMedCrossRef
74.
Shibuya S, Xia Z, Sugimoto M, Ueda N, Haba R, Kakehi Y (2014) The phytotherapeutic agent, eviprostat, suppresses stromal proliferation and inflammation even after establishment of nonbacterial prostatitis in the rat prostate. Urology 83:528–534PubMedCrossRef
75.
Tsunemori H, Sugimoto M, Xia Z, Taoka R, Oka M, Kakehi Y (2011) Effect of the phytotherapeutic agent eviprostat on inflammatory changes and cytokine production in a rat model of nonbacterial prostatitis. Urology 77(1507):e1515–e1520
76.
Wilson MJ, Woodson M, Wiehr C, Reddy A, Sinha AA (2004) Matrix metalloproteinases in the pathogenesis of estradiol-induced nonbacterial prostatitis in the lateral prostate lobe of the Wistar rat. Exp Mol Pathol 77:7–17PubMedCrossRef
77.
Nickel JC, True LD, Krieger JN, Berger RE, Boag AH, Young ID (2001) Consensus development of a histopathological classification system for chronic prostatic inflammation. BJU Int 87:797–805PubMedCrossRef
Metadata
Title
Histopathological classification criteria of rat model of chronic prostatitis/chronic pelvic pain syndrome
Authors
Xianjin Wang
Shan Zhong
Tianyuan Xu
Leilei Xia
Xiaohua Zhang
Zhaowei Zhu
Minguang Zhang
Zhoujun Shen
Publication date
01-02-2015
Publisher
Springer Netherlands
Published in
International Urology and Nephrology / Issue 2/2015
Print ISSN: 0301-1623
Electronic ISSN: 1573-2584
DOI
https://doi.org/10.1007/s11255-014-0868-x

Other articles of this Issue 2/2015

International Urology and Nephrology 2/2015 Go to the issue

Urology - Original Paper

Evaluation of the utility of different scoring systems (FGSI, LRINEC and NLR) in the management of Fournier’s gangrene

Urology – Original Paper

How are we protecting ourselves from radiation exposure? A nationwide survey

Urology – Letter to the Editor

A potential biomarker for objective diagnosis of overactive bladder: urinary nerve growth factor

Urology – Original Paper

Prospective study of the Transurethral Suprapubic endo-Cystostomy (T-SPEC®): an ‘inside-out’ approach to suprapubic catheter insertion

Nephrology - Original article

Secondary hyperparathyroidism is associated with pulmonary hypertension in older patients with chronic kidney disease and proteinuria

Nephrology – Original Paper

The placement of peritoneal dialysis catheters: a prospective randomized comparison of open surgery versus “Mini-Perc” technique
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits